Switching Anti–Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration

What do we know about anti–vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD)? Briefly, I think we know that pegaptanib is safe, but compared with newer anti-VEGF drugs, not as effective, and ranibizumab and aflibercept are safe and effective. To my view, bevacizumab seems to be safe and effective with outcomes similar to those seen with ranibizumab. I think we know that monthly and as-needed treatment approaches for bevacizumab and ranibizumab yield similar outcomes. We also know that treating at 3-month intervals with ranibizumab yields suboptimal outcomes. We know that bevacizumab therapy is less expensive than (Read more...)

Full Story →